Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Splenomegaly 1Primary Myelofibrosis 1Leukemia, Myeloid, Acute 1Leukemia 1Anemia, Refractory 1Anemia 1

Interventions

Cyclophosphamide 30fludarabine phosphate 25Cyclosporine 25Busulfan 20Mycophenolic Acid 18Peripheral Blood Stem Cell Transplantation 17Cord Blood Stem Cell Transplantation 16Antilymphocyte Serum 16Whole-Body Irradiation 15Radiotherapy 15Methotrexate 12Methylprednisolone 10Filgrastim 10Cytarabine 8Etoposide 7Tacrolimus 6Melphalan 6sargramostim 5fludarabine 4Thiotepa 4Granulocyte Colony-Stimulating Factor 4Decitabine 4Cyclosporins 4Azacitidine 4merphos 3Transplantation 3Arsenic Trioxide 3bryostatin 1 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × ON 01910 × Classical hematology × Clear all
NCT00854945 2017-06-26

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Traws Pharma, Inc.

Phase 1/2 Completed
36 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡